Bullish Case: Lonvo-z's Phase 3 win (87% attack reduction, 62% attack-free) and submitted BLA with a decision expected by March 2027 give NTLA a defined binary catalyst toward a ~$7B US HAE opportunity. Clinical holds on nex-z were lifted, calls outtraded puts 22%, and bullish risk runs 89% above bearish. Helium's density places heavy mass at $12–13 with a fat upside shoulder toward $18, and Jan-2027 calls (73–75 IV) preserve cheap convexity into the approval window.

Bearish Case: Lonvo-z approval is likely already priced; shares fell on the Phase 3 release before recovering. Nex-z's lifted holds leave persistent liver-safety overhang across two Phase 3s with Regeneron. NTLA is unprofitable with no revenue, the term structure is backwardated signaling near-term event risk, and far-OTM put IV (82–164%) plus the return surface's recurring negative-return bands show the left tail is actively defended. Dilution or an FDA data request could drive swift −20–35% moves.

Potential Outcomes:

1. ~48%: Range-bound $11–$14 into Jan expiries—no major headline; backwardated IV decays. Falsified by FDA/BLA or nex-z news.
2. ~18%: Positive FDA acceptance/early priority or nex-z progress → $15–$19. Falsified by silent FDA or safety re-hold.
3. ~17%: Dilution (S-3/ATM) or nex-z safety signal → $9–$11. Falsified by filing absence.
4. ~10%: BLA delay/CRL risk repricing → $8–$11.
5. ~7%: Binary shock beyond ±35% (approval surprise or trial halt).

October 03, 2026